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Abstract: The authors report two cases of rebound phenomenon treated with intravitreal 
  triamcinolone acetonide in Vogt-Koyanagi-Harada (VKH) disease. Patients in the acute phase 
of VKH disease were treated with high-dose intravenous (IV) methylprednisolone (1 g/day) 
for 3 days. Serous retinal detachment decreased and visual acuity improved during IV steroid 
treatment. After switching to oral steroid treatment, choroiditis and visual acuity worsened. An 
injection of triamcinolone acetonide (4 mg) into the vitreous resulted in gradual resolution of 
subretinal fluid and improvement of visual acuity. Systemic steroids were tapered to discontinu-
ation without a relapse of inflammation. Adjuvant intravitreal triamcinolone is useful in the 
management of the rebound phenomenon in VKH disease.
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Introduction
Vogt-Koyanagi-Harada (VKH) disease has a unique natural history that comprises four 
phases: prodromal, acute uveitic, chronic, and chronic recurrent. Of these phases, the 
acute phase requires intensive treatment.1 Delayed or inadequate control of inflam-
mation at this phase may lead to the recurrent phase, which is difficult to manage. 
Although many physicians popularly use high-dose intravenous (IV) steroids for 3 days 
before switching to oral steroids, the optimal management for choroidal inflammation 
in the acute phase has not been established. The authors report two cases of rebound 
choroidal inflammation after transitioning from high-dose IV steroids to oral steroids 
that were managed successfully using adjuvant intravitreal steroid injection.
Case report 1
A 43-year-old woman presented with headache, tinnitus, and decreased visual acuity. 
She had no history or evidence of penetrating ocular trauma, ocular surgery, or ocular 
or systemic diseases. Her best-corrected visual acuity was 20/60 in the right eye and 
20/40 in the left. The anterior segment had no signs of inflammation and fundus 
examination revealed bullous serous retinal detachments in both eyes. Multiple pinpoint 
leakages and late pooling within subretinal fluid (SRF) were detected using fluorescein 
angiography (FA) (Figure 1A and B). Intra- and SRF with septa was noted by spectral 
domain optical coherence tomography (SD-OCT) using the Cirrus™ HD-OCT (Carl 
Zeiss Meditec AG, Jena, Germany) (Figure 1C). A diagnosis of incomplete VKH disease 
was determined and treatment with high-dose IV methylprednisolone pulse therapy 
(1 g/day) was administered for 3 days. During IV steroid treatment, the patient’s SRF Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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decreased and her vision improved to 20/40 in both eyes 
(Figure 1D). Methylprednisolone therapy was then switched 
to oral prednisolone (1 mg/kg/day). At 3 days after switching, 
the patient’s SRF increased and her vision worsened to 20/160 
and 20/60 (Figure 1E). High-dose IV methylprednisolone 
was then restarted. The patient’s SRF reduced and her visual 
A
B
C
D
E
F
G
H
Figure 1 Case 1. (A) Fundus photograph shows bullous retinal detachment in 
both eyes at presentation. (B) Multiple leakages and poolings in the late phase 
of  fluorescein  angiography  were  detected.  (C)  Optical  coherence  tomography 
image represents intra- and subretinal fluid (SRF) with subretinal septa. (D) srF 
was considerably reduced at 3 days after intravenous (IV) pulse steroid therapy. 
(E) srF increased at 3 days after changing treatment from IV to oral steroids. 
(F) srF resolved at 4 days after IV pulse steroid therapy was restarted. (G) Bullous 
retinal detachment developed again after changing to oral steroids. (H) srF resolved 
after intravitreal injection of triamcinolone acetonide.
  acuity improved remarkably after 4 days (Figure 1F). Systemic 
steroids were then changed again to an oral formulation. After 
restarting oral steroid treatment (1.3 mg/kg/day), the patient’s 
vision decreased gradually as bullous retinal detachment devel-
oped (Figure 1G). While maintaining her oral steroid dose, 
triamcinolone acetonide 4 mg was injected intravitreally as an 
adjunctive treatment. The SRF resolved gradually with visual 
acuity improvement. During a follow-up period of 13 months, 
intraocular pressure was stable and cataract did not develop. 
Systemic steroids were tapered to discontinuation without a 
relapse of inflammation (Figure 1H).
Case report 2
A 33-year-old man complained of tinnitus and visual dis-
turbance involving the right eye for 2 days. His vision was 
20/120 in the right eye and 20/20 in the left. Serous retinal 
detachment was found in both eyes. FA showed multiple pin-
point leakages and late pooling (Figure 2A and B). SD-OCT 
detected multilobulated serous detachments   (Figure 2C). 
Evaluations for causes other than VKH disease were negative. 
The patient was treated for 3 days with high-dose IV methyl-
prednisolone (1 g/day) followed by 5 days with oral steroids 
(1 mg/kg/day). Serous retinal detachment decreased and his 
vision improved to 20/50 in the right eye during the 3 days 
while on IV steroid treatment (Figure 2D). After 5 days of oral 
steroid treatment, the patient’s SRF increased and his vision 
worsened (Figure 2E). Adjuvant triamcinolone acetonide 
4 mg was injected into the vitreous of both eyes. Visual acu-
ity and serous detachment improved (Figure 2F). During a 
follow-up period of 22 months, an elevation of intraocular 
pressure did not develop and systemic steroids were success-
fully tapered without a relapse of inflammation.
Discussion
VKH disease is a disorder of T-cell-mediated autoimmunity 
directed against melanocytes in the eye, central nervous 
system, auditory system, and skin. The typical treatment 
for VKH disease is high-dose systemic steroids, followed 
by slow tapering over 3–6 months. Although the route of 
  administration of steroids has been reported to have no dif-
ference in visual acuity or on the development of visually 
significant complications,2 many physicians prefer an initial 
therapy of prompt and intensive high-dose IV methylpredni-
solone over 3 days. It is well known that most patients show 
a resolution of serous retinal detachment and an improvement 
of vision within days of receiving IV pulse steroid therapy.3
To the authors’ knowledge, rebound phenomenon 
in patients with VKH disease has not been reported 
before. It may be underestimated because the dosage of oral Clinical Ophthalmology
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steroids after transitioning from the IV regimen is similar to 
the starting dosage in oral steroid monotherapy and the treat-
ing physicians do not expect a relapse of inflammation.
However, these two cases presented with relapsing chor-
oiditis after a change in the steroid administration route. It 
was considered that control of the inflammation was required, 
because delayed or inadequate control of inflammation may 
lead to the chronic recurrent phase, which is difficult to   manage. 
In the first case of rebound phenomenon, choroiditis was 
relapsed even after the second session of IV pulse steroid 
therapy. As prolonged systemic treatment with high-dose ste-
roids was expected, intravitreal triamcinolone acetonide was 
administered to avoid the side effects of systemic steroids.4–6 
The second case of rebound phenomenon could be managed 
successfully with adjuvant intravitreal triamcinolone while 
maintaining the tapering schedule of oral steroids.
Conclusion
The rebound phenomenon may have been secondary to 
either an insufficient oral steroid dose or the difference of 
the dose between IV and oral regimens when transitioning 
formulations. An intermediate dose may be considered 
between two formulations to prevent this untoward event. 
If rebound phenomenon develops, adjuvant intravitreal injec-
tion of triamcinolone acetonide is effective in controlling 
inflammation.
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Figure 2 Case 2. (A) Fundus photograph shows serous retinal detachment in both 
eyes. (B) Multiple leakages and poolings in the late phase of fluorescein angiography 
were detected. (C) Optical coherence tomography image represents intraretinal 
fluid accumulation and subretinal septa in the multilobular serous detachment at 
initial visit. (D) Subretinal fluid (SRF) was remarkably reduced at 3 days after high-
dose intravenous pulse steroid therapy. (E) srF increased at 5 days after starting 
oral steroids. (F) After intravitreal injection of adjuvant triamcinolone acetonide, 
srF resolved and vision recovered. The patient was successfully tapered off oral 
steroids without rebound phenomenon.